Beyond the Psychedelic Competitive Moat: Chasing the Patent Dragon
Here, we examine hype in the context of a perennial tension at the heart of patenting communication: between advertising innovation and keeping it secret.
Patent Law
-
Read more: Beyond the Psychedelic Competitive Moat: Chasing the Patent Dragon -
Read more: The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
-
Read more: Is Messenger RNA Patent-Eligible? Is Messenger RNA Patent-Eligible?
Amid ongoing patent disputes over the mRNA platform, a significant scientific question remains unanswered: whether mRNA itself even is patent eligible.
-
Read more: COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues
An explanation of the key patents at stake in the intellectual property dispute between Moderna and Pfizer/BioNTech over COVID-19 vaccines.
-
Read more: Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA
While it may not seem controversial to promote honesty before the USPTO, a recent Federal Register Notice goes far beyond requiring candor.
-
Read more: No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge
This post explains why Moderna’s cynical attempt to take back its COVID-19 vaccine patent pledge should fail.
-
Read more: Introducing Affiliated Researchers for the Project on Psychedelics Law and Regulation Introducing Affiliated Researchers for the Project on Psychedelics Law and Regulation
We are excited to welcome our inaugural group of affiliated researchers for the Project on Psychedelics Law and Regulation (POPLAR).
-
Read more: Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna? Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this research.
-
Read more: The Civil Rights Challenge to Gene Patenting The Civil Rights Challenge to Gene Patenting
The ACLU mounted an unprecedented challenge the entire practice of gene patenting in America. And, against the odds, they won.
-
Read more: Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court
An ongoing patent battle over omega-3 fatty acids may have broad implications for the marketing of generic drugs.
